Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 2/20 | 0.50 |
| ▸ | NAMPT | P43490 | 8/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115740 | 0.91 | ROCK1 (0.52) | ROCK1EPHX1POLBMAPTRAB9A | |
| SCHEMBL3106601 | 0.90 | ROCK1 (0.47) | ROCK1NAMPTEPHX1POLBMAPT | |
| SCHEMBL3115126 | 0.89 | ROCK1 (0.46) | ROCK1NAMPTEPHX1POLBMAPT | |
| SCHEMBL3113673 | 0.88 | MAPK11 (0.50) | ROCK1HPGDPOLBMAPTRAB9A | |
| SCHEMBL13158409 | 0.87 | TP53 (0.52) | ROCK1NAMPTEPHX1HPGDMAPT | |
| SCHEMBL3117396 | 0.86 | ROCK1 (0.54) | ROCK1POLBMAPTRAB9ANPC1 | |
| SCHEMBL3109629 | 0.86 | ROCK1 (0.47) | ROCK1EPHX1POLBMAPTRAB9A | |
| SCHEMBL3114706 | 0.85 | ROCK1 (0.43) | ROCK1NAMPTEPHX1MAPTRAB9A | |
| SCHEMBL3099742 | 0.84 | ROCK1 (0.48) | ROCK1POLBMAPTRXFP1 | |
| SCHEMBL3107222 | 0.83 | ROCK1 (0.45) | ROCK1EPHX1POLBMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1867331-A1 | TRIAZOLE DERIVATIVE AND THE USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105253-A1 | Triazole Derivative and Use Thereof | F2R, HRH4, F2RL3 | ROCK1 1430/4885NAMPT 1494/4885EPHX1 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.